公开(公告)号：US20250059280A1

公开(公告)日：2025-02-20

申请号：US18806311

申请日：2024-08-15

Applicant: AbbVie Inc.

Inventor： Ana Gabriela Pires dos Santos ,  Preethi Krishnan ,  Mong-Jen Chen ,  Aline Goebel ,  Neha Thakre ,  Insa Winzenborg ,  Tanaya Vaidya

IPC: C07K16/28 ,  A61K9/00 ,  A61P31/18

Abstract: The invention described herein relates to methods of treating HIV infection comprising administering an anti-PD-1 monoclonal antibody and/or an anti-α4β7 monoclonal antibody.

公开(公告)号：US20250049789A1

公开(公告)日：2025-02-13

申请号：US18797097

申请日：2024-08-07

Applicant: AbbVie Inc.

Inventor： Andrea Chiricozzi

IPC: A61K31/4985 ,  A61K9/00 ,  A61P17/14

Abstract: The present disclosure is directed to methods for treating alopecia areata (AA) using the selective JAK1 inhibitor upadacitinib.

公开(公告)号：US20250042894A1

公开(公告)日：2025-02-06

申请号：US18709204

申请日：2022-11-10

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Andrew Bogdan ,  Christos Economou ,  Jennifer M. Frost ,  Philip R. Kym ,  Spencer O. Scholz ,  Zhaoming Xiong

IPC: C07D417/14 ,  A61K31/433 ,  C07D417/04

Abstract: The present invention provides for compounds of Formula (I) wherein R1, has any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.

公开(公告)号：US20250032631A1

公开(公告)日：2025-01-30

申请号：US18915981

申请日：2024-10-15

Applicant: AbbVie Inc.

Inventor： Emily Jean Faivre ,  Andrew C. Phillips ,  Regina M. Reilly ,  Eoghainin O'Hainmhire

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/18

Abstract: The present disclosure provides SEZ6 antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

公开(公告)号：US20250017932A1

公开(公告)日：2025-01-16

申请号：US18903555

申请日：2024-10-01

Applicant: AbbVie Inc.

Inventor： Mohamad Shebley ,  Ling Cheng ,  Pooja Manchandani

IPC: A61K31/513 ,  A61K9/00 ,  A61K31/567 ,  A61P15/00 ,  A61P35/00

Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole) or a CYP3A4 substrate (e.g., ethinyl estradiol and/or levonorgestrel).

公开(公告)号：US20240417458A1

公开(公告)日：2024-12-19

申请号：US18710958

申请日：2022-11-16

Applicant: Disc Medicine, Inc. ,  AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Brian MacDonald ,  John Quisel ,  Will Savage ,  Hua Yang ,  Jonathan Yu ,  Min Wu ,  Maria Beconi ,  Jennifer M. Perez ,  Bernhard Mueller ,  Andreas Popp

IPC: C07K16/28 ,  A61P7/06

Abstract: Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a subject having an anemia associated with chronic kidney disease and/or kidney disease in a subject that has a level of glomerular filtration rate lower than one or more thresholds.

公开(公告)号：US20240398787A1

公开(公告)日：2024-12-05

申请号：US18437732

申请日：2024-02-09

Applicant: AbbVie Inc. ,  Allergan Pharmaceuticals International Limited

Inventor： Kumar Budur ,  Ludmyla Rekeda ,  Willie R. Earley

IPC: A61K31/495 ,  A61P25/24

Abstract: The present disclosure provides methods for the treatment of major depressive disorder by administering cariprazine or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12129294B2

公开(公告)日：2024-10-29

申请号：US18105316

申请日：2023-02-03

Applicant: AbbVie Inc.

Inventor： Gregg Timony ,  Sheila Gujrathi ,  Robert Peach ,  Allan Olson

IPC: C07K16/24 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/395 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06

CPC classification number: C07K16/244 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06 ,  C07K2317/56

Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

公开(公告)号：US20240350524A1

公开(公告)日：2024-10-24

申请号：US18627239

申请日：2024-04-04

Applicant: ABBVIE INC.

Inventor： Ahmed H. SALEM ,  Johannes WOLFF ,  John HAYSLIP

IPC: A61K31/706 ,  A61K31/496 ,  A61P35/02

CPC classification number: A61K31/706 ,  A61K31/496 ,  A61P35/02

Abstract: The invention described herein relates to relates to dosing methods for a human subject with acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation, comprising administering to a human subject venetoclax in combination with azacitidine, wherein the human subject has previously undergone allogeneic hematopoietic stem cell transplantation.

公开(公告)号：US12110298B2

公开(公告)日：2024-10-08

申请号：US18369272

申请日：2023-09-18

Applicant: AbbVie Inc.

Inventor： Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmad Y. Sheikh

IPC: C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.